|
Market Closed -
Nasdaq
16:00:00 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 1.830 USD | +1.67% |
|
-22.13% | -37.97% |
| 08-18 | Cellectar Biosciences, Inc. - Special Call | |
| 08-13 | Cellectar Biosciences, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
Company Valuation: Cellectar Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 40.57 | 16.05 | 34.04 | 12.34 | 12.51 | 17.3 | - | - |
| Change | - | -60.44% | 112.09% | -63.75% | 1.37% | 38.29% | - | - |
| Enterprise Value (EV) | 40.57 | 16.05 | 34.04 | 12.34 | 12.51 | 17.3 | 17.3 | 17.3 |
| Change | - | -60.44% | 112.09% | -63.75% | 1.37% | 38.29% | 0% | 0% |
| P/E | -1.54x | -0.42x | -0.89x | -0.25x | -0.35x | -0.75x | -0.96x | -3.24x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.07x | 0x | 0x | 0x | 0x | 0x | 0x |
| Capitalization / Revenue | - | - | - | - | - | - | 2.26x | 0.24x |
| EV / Revenue | - | - | - | - | - | - | 2.26x | 0.24x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.54x | -0.48x | -1.81x |
| EV / FCF | - | - | - | -0x | - | -0.51x | -0.4x | -1.04x |
| FCF Yield | - | - | - | -386% | - | -197% | -253% | -96% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -129 | -121.5 | -93.3 | -36.6 | -8.35 | -2.428 | -1.915 | -0.565 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 7.649 | 71.64 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -24.13 | -28.81 | -38.96 | -51.78 | -22.98 | -31.98 | -36.14 | -9.575 |
| Net income 1 | -24.12 | -28.6 | -37.98 | -44.58 | -21.79 | -31.63 | -37.38 | -13.69 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 199.200 | 51.300 | 83.100 | 8.970 | 2.950 | 1.830 | 1.830 | 1.830 |
| Nbr of stocks (in thousands) | 204 | 313 | 410 | 1,376 | 4,240 | 9,452 | - | - |
| Announcement Date | 3/21/22 | 3/9/23 | 3/27/24 | 3/13/25 | 3/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.74x | - | - | - | 17.01M | |
| 33.65x | 12.19x | 24.78x | 0.59% | 1,055B | |
| 30.17x | 6.71x | 18.78x | 1.98% | 654B | |
| 33.43x | 7.82x | 16.17x | 2.59% | 467B | |
| 19.59x | 4.78x | 11.84x | 2.78% | 348B | |
| 20.4x | 5.31x | 13.17x | 3.01% | 275B | |
| 21.19x | 4.39x | 12.5x | 2.01% | 258B | |
| 26.19x | 6.82x | 12.15x | 2.43% | 224B | |
| -45.65x | 6.64x | 25.94x | 2.18% | 187B | |
| 11.33x | 4.13x | 8.58x | 4.44% | 171B | |
| Average | 14.95x | 6.53x | 15.99x | 2.45% | 363.84B | |
| Weighted average by Cap. | 24.18x | 7.87x | 18.13x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CLRB Stock
- Valuation Cellectar Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
